Amazon jobs salary revealed: How much can Indian engineers earn at Amazon US on an H-1B visa?
Publicly disclosed filings for the first quarter of 2025 show that Amazon employed around 11,300 foreign nationals in the US on H-1B visas. These documents provide a clear look at how much the company is offering across tech and business roles.
Software Development Engineers at Amazon.com Services earn between $85,384 and $263,700 annually. At Amazon Web Services, a similar role pays between $84,094 and $223,600. Data scientists, another high-demand profile, are paid up to $230,900. Technical product managers can make as much as $235,200, while managers in software development can command up to $287,700.
Here's a quick glance at some key salary ranges across roles for H-1B employees at Amazon US:
Software Development Engineer: $85,384 – $263,700
$85,384 – $263,700 Data Scientist: $92,040 – $230,900
$92,040 – $230,900 Product Manager (Technical): $136,843 – $235,200
$136,843 – $235,200 Software Development Manager: $148,950 – $287,700
$148,950 – $287,700 Data Engineer: $70,262 – $236,344
$70,262 – $236,344 Financial Analyst: $94,300 – $204,028
$94,300 – $204,028 Solutions Architect: $112,474 – $225,000
According to an Amazon spokesperson, compensation packages are designed based on the employee's level, role, and location. The company reviews its pay structure regularly to stay competitive and attract skilled professionals from across the globe.
Amazon jobs salary in US: Detailed List
Amazon Data Services
Software Development Engineer: $108,826 – $223,600
Amazon Development Center US
Software Development Engineer: $95,493 – $260,600
Amazon Web Services
Business Intelligence Engineer: $96,678 – $176,012
Enterprise Account Engineer: $103,605 – $238,965
Professional Services: $105,997 – $218,200
Software Development Engineer: $84,094 – $223,600
Solutions Architect: $112,474 – $225,000
Support Engineer (External): $63,835 – $160,000
Amazon.com Services
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 minutes ago
- Time of India
Railway Minister: 'Make in India' boosting rail exports, coaches sent to Australia, bogies to UK
Railway Minister Ashwini Vaishnaw visited Alstom's coach manufacturing unit in Vadodara, where metro and intercity train coaches are being built for Indian and international routes. He highlighted India's growing rail exports under the 'Make in India, Make for the World' vision, with coaches and components being shipped to countries including Australia, Canada, UK, Saudi Arabia, and France. Show more Show less
Mint
3 minutes ago
- Mint
IT sector not broken, but evolving, says TRUST MF's CIO Mihir Vohra; shares top sectoral bets
Mihir Vora, CIO, TRUST Mutual Fund, believes that the Indian stock market could step out of its consolidation zone once global volatility subsides and investor focus returns to earnings. Meanwhile, Vohra remains unperturbed by the ongoing FII selloff, as DII support and SIP inflows bolster confidence in equity demand. He is bullish on select sectors like infrastructure, logistics, and defence suppliers, NBFCs, among others. Edited excerpts: The Nifty has been churning in a tight band for several weeks. The domestic and global macroeconomic and geopolitical setup has many moving parts, and markets are probably waiting for a reduction in uncertainty. Globally, US trade negotiations are still on, and the US Dollar continues to be weak in spite of high bond yields. Domestically, the long-term macro parameters are healthy – low inflation, improving current account deficit and fiscal deficit. Consumption indicators are a mixed bag, and credit growth has not yet picked up in spite of ample liquidity and rate cuts. In the short term, the earnings season has seen a mix of negative and positive surprises. Sustained earnings growth remains key for the market. If global volatility subsides and investor focus returns to domestic earnings, that could be enough to lift sentiment. Clarity on a U.S.–India trade agreement by the August 1 deadline can also be a catalyst. Foreign portfolio investors have turned cautious again — derivative positioning suggests the most bearish sentiment in months. That may continue until we get clear signals on U.S. Fed policy or trade developments. In the medium to long-term, if the US Dollar continues to remain relatively weak, we should see sustained flows to countries like India. We see FPI selling as cyclical rather than structural. In time, India's superior long-term macro, demographics and higher growth should bring global interest back. India also has a strong internal support system: domestic institutions remain net buyers, and record retail SIP flows continue to underpin demand. Overall, we have an underweight stance in the IT sector. We are tackling the sector exposure selectively, preferring midcap IT names and digital infra providers with stronger growth visibility, rather than overcrowded large caps. Even within the blue-chips, firms executing well on AI/automation and client-based cost takeout remain interesting. The sector isn't broken — it's just evolving. While the leading IT giants delivered subdued numbers — flat revenues, soft global deal wins — valuations are now trading closer to historical norms than early 2024 extremes. Our growth conviction remains highest in capex, power transmission, infrastructure logistics, and defence suppliers—segments with visible order books, operating leverage, and a longer runway of growth. However, we are selective as these segments have become quite popular and valuations are not uniformly attractive. Financials offer opportunities in NBFCs and banks, with expectations of improving credit growth and asset quality. Auto ancillaries and engineering services/export plays are also showing promise as the global capex cycle recovers. In healthcare, the stories are more stock-specific, and we like the CDMO space and hospitals. After sharp rallies in many names, investors have started booking profits. The pullback is a natural consolidation, not a capitulation. The long-term fundamentals — rising defence budgets, dual-use platform opportunities, and improving export arcs — remain intact. Stock selection is critical now. We favour robust balance sheets, clear execution histories, and firms with pipeline visibility. Yes, we launched our third equity fund, the Multicap Fund. This continues our efforts to offer funds in all the core categories to our investors and distributors, the first two being the Flexi Cap and Small Cap funds. The Multicap category is a core category and is suitable for most investors who want a diversified exposure to the stock market. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
3 minutes ago
- Mint
Nifty Pharma Index rises 1% amid weak India Stock Markets: Cipla and Laurus Labs among key gainers
Stock Market Today: The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped 0.3-0.4% during the intraday trades. Cipla and Laurus Labs stood among the key gainers The Nifty Pharma index, showing its resilience, gained more than 1% during the intraday trades. The Nifty Pharma Index, which opened at 22690.50 on Monday, went to scale highs of 22,908.40, marking gains of more than 1% over the previous day's close of 22662.70. Laurus Labs, with gains of more than 7%, followed by Cipla, with gains of close to 2%, stood among key gainers. Glenmark Pharmaceuticals and Gland Pharma also gained more than 1%, helping drive gains. Nifty Pharma and Healthcare index have been showing resilience amid volatile stock markets since last few weeks While Nifty Pharma & Healthcare are the lone warriors displaying outperformance amidst this downfall in the markets, we expect sectors such as IT, Defense, Oil & Gas, Realty & CPSE to appear bearish and may continue to underperform in the near term, given their weak price structures and lackluster momentum indicators., said Sudeep Shah, Vice President and Head of Technical and Derivative Research, SBI Securities Technically, Cipla, Apollo Hospital are likely to outperform in the short term, as per Shah. The Indian Pharma index performance is also being helped by strong Indian Pharma market growth. The IPM growth during the month of June 2025 stood at a strong 11.5%, as per reports. Glemmark Pharmaceuticals, JB Chemicals and Pharmaceuticals, Mankind Pharma FDC Ltd, Alkem, Zydus, and Torrent were among the key outperformers as per Nuvama. While the pharma market is growing, the challenge is provided by rising generic sales and Jan Aushadhi Kendras. However, amidst challenges, Within formulations, Sun, Cipla, Lupin and Emcure are the top picks. of Kotak Institutional Equities Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
